Neuropharmacoeconomics

Acta Neurologica Taiwanica

Volumn 13, Issue 2, 2004, Pages 87-96

  Chiu, Hou Chang ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cost effectiveness analysis; Cost utility analysis; DALY; Pharmacoeconomics; QALY

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; ECONOMIC EVALUATION; NEUROLOGY; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW;

COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; NEUROLOGY; QUALITY-ADJUSTED LIFE YEARS;

EID: 3042790159     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Murry MI, Halpern MT, Leppik IE. Cost refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-48.
2. Chiu HC, Tsai SY. Pharmacoeconomics (III): cost-effectiveness analysis of thrombolytic therapy in acute ischemic stroke. Formosa J Med 2003;7:453-8.
3. Ernst RL, Hay JW, The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-4,
4. Souetre EJ, Qing W, Vigoureux I, et al. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Int Psychogeriat 1995;7:115-22.
5. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease. Pharmacoeconomics 2000;17:351-60.
6. Fenn P, Gray A. Estimating long-term cost savings from treatment of Alzheimer's disease. Pharmacoeconomic 1999;16:165-74.
7. Knopman D, Schneider L, Davis K, et al. Long-term tacrine treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.
8. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezeil in the treatment of Alzheimer's disease. Clin Ther 1998;20:838-50.
9. Cummings JL. Cholinesterase inhibitors: expanding applications. Lancet 2000;356:2024-5.
10. Chambers MG, Koch P, Hatton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value in Health 2002;5:82-97.
11. Fagan SC, Morgenstern LB, Retiha A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883-90.
12. Chiu HC. Pharmacoeconomics (V): evaluation of medical treatment of Parkinson's disease. Formosa J Med 2003; 7:805-10.
13. Chiu HC. Pharmacoeconomics (VI): evaluation of lipid lowering drugs. Formosa J Med 2003;7:130-4.
14. Rubenstein LM, Voelker MD, Chrischilles EA, et al. The usefulness of the Functional Status Questionnaire (FSQ) and the medical outcomes study short form (SF-36) in Parkinson's disease research. Qual Life Res 1998;7:279-90.
15. Hilleman DE, Heineman SM, Foral PA. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES Study. Pharmacotherapy 2000;20:819-22.
16. Edelson JT, Weinstein MC, Tosteson AN, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263:407-13.
17. Littenberg B. A practice guideline revisited: screening for hypertension. Ann Intern Med 1995;122:937-9.
18. Chiu HC. Pharmacoeconomics (VII): evaluation of antihypertension drugs. Formosa J Med 2003;7:270-3.